IDEAYA Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.09.24	IDEAYA Announces Positive Interim Phase 2 Data For Darovasertib In Neoadjuvant Uveal Melanoma (RTTNews)
10.07.24	IDEAYA Biosciences Announces Pricing Of Public Offering Of Common Stock And Pre-funded Warrants (RTTNews)
07.07.24	D-Day For IDEAYA - IDE397 Data To Be Unveiled Tomorrow (RTTNews)
12.03.24	IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer (RTTNews)
20.02.24	IDEAYA Biosciences Q4 Results Misses Estimates (RTTNews)
05.02.24	Biotech High-Flyers That Just Hit 52-Week Highs (RTTNews)
29.12.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08.12.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
05.12.23	IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event (PR Newswire)
04.12.23	IDEAYA To Evaluate IDE397 In Combination With Gilead's Trodelvy - Quick Facts (RTTNews)
04.12.23	IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer (PR Newswire)
03.12.23	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 (PR Newswire)
07.11.23	IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
01.11.23	IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference (PR Newswire)
27.10.23	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
27.10.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
25.10.23	IDEAYA Biosciences Prices Public Offering Of 5 Mln Shares Of Common Stock At $23.50/shr (RTTNews)
25.10.23	IDEAYA Announces Pricing of Public Offering (PR Newswire)
24.10.23	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
23.10.23	IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Leth... (PR Newswire)
17.10.23	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma (PR Newswire)
16.10.23	IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma (PR Newswire)
09.10.23	IDEAYA Biosciences Selects Werner Helicase Inhibitor Development Candidate With GSK (RTTNews)
09.10.23	IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day (PR Newswire)
06.10.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
27.09.23	IDEAYA Biosciences: IDE161 Granted Fast Track Status By FDA (RTTNews)
27.09.23	IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer (PR Newswire)
26.09.23	IDEAYA: Potential First-in-Class PARG Inhibitor IDE161 Gets FDA Fast Track Designation (RTTNews)
26.09.23	IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tu... (PR Newswire)
11.09.23	IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors (PR Newswire)
05.09.23	IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events (PR Newswire)
21.08.23	IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101 (RTTNews)
21.08.23	IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705) (PR Newswire)
16.08.23	IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma (PR Newswire)
10.08.23	IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
02.08.23	IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors (PR Newswire)
01.08.23	IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event (PR Newswire)
28.07.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
30.06.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
22.06.23	IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy (PR Newswire)
12.06.23	IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types (PR Newswire)
30.05.23	IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events (PR Newswire)
26.05.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
22.05.23	IDEAYA: FDA Approves To Proceed With Evaluation Of IDE397 In Combination With AMG 193 (RTTNews)
22.05.23	IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors (PR Newswire)
16.05.23	IDEAYA Announces Amended Clinical Trial Collaboration And Supply Agreements With Pfizer (RTTNews)
16.05.23	IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma (PR Newswire)
09.05.23	IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
01.05.23	IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event (PR Newswire)
28.04.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu IDEAYA Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten